SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (11100)4/5/2017 2:02:15 PM
From: tuck  Respond to of 12215
 
It would be interesting to see follow-up work in an in vivo knee injury model with actual administration of a KOR agonist. While mice are notoriously bad at completing WOMAC forms, the parameters explored in this study - GAG and lubricin production, matrix degradation - could again be measured. Not sure if this could be done in humans without hopelessly high dropout rates (how many cartilage biopsies would this require? Is there a less invasive way via imaging?).

Cheers, Tuck



To: Biotech Jim who wrote (11100)4/6/2017 3:07:12 PM
From: tuck  Respond to of 12215
 
Re CARA human trials versus in vitro and in vivo data you posted: Let me be clearer about my concern here. If I correctly understood the dosing regimens in these murine experiments versus those in human trials, and the time it took for these positive effects to show up in in the murine models, the human P2 trial is not of sufficient duration for said effects to show up. Maybe in a longer P3 program they would? Appreciate your thoughts.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News